Literature DB >> 18685610

Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation.

O Benjamini, M Koren-Michowitz, N Amariglio, N Kroger, A Nagler, A Shimoni.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18685610     DOI： 10.1038/leu.2008.215

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  8 in total

Review 1.  What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?

Authors:  Paola Guglielmelli; Giada Rotunno; Annalisa Pacilli; Alessandro Maria Vannucchi
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

2.  Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia.

Authors:  Karen K Ballen; Ann E Woolfrey; Xiaochun Zhu; Kwang Woo Ahn; Baldeep Wirk; Mukta Arora; Biju George; Bipin N Savani; Brian Bolwell; David L Porter; Ed Copelan; Gregory Hale; Harry C Schouten; Ian Lewis; Jean Yves Cahn; Joerg Halter; Jorge Cortes; Matt E Kalaycio; Joseph Antin; Mahmoud D Aljurf; Matthew H Carabasi; Mehdi Hamadani; Philip McCarthy; Steven Pavletic; Vikas Gupta; H Joachim Deeg; Richard T Maziarz; Mary M Horowitz; Wael Saber
Journal:  Biol Blood Marrow Transplant       Date:  2012-03-24       Impact factor: 5.742

3.  JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.

Authors:  Alessandro M Vannucchi; Lisa Pieri; Paola Guglielmelli
Journal:  Ther Adv Hematol       Date:  2011-02

Review 4.  Reduced-intensity conditioning followed by allogeneic hematopoietic stem cell transplantation in myelofibrosis.

Authors:  Haefaa Alchalby; Nicolaus Kröger
Journal:  Curr Hematol Malig Rep       Date:  2010-04       Impact factor: 3.952

5.  Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis.

Authors:  David S Snyder; Joycelynne Palmer; Karl Gaal; Anthony S Stein; Vinod Pullarkat; Firoozeh Sahebi; Nyana Vora; Ryotaro Nakamura; Stephen J Forman
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-26       Impact factor: 5.742

Review 6.  Monitoring residual disease in the ph-negative myeloproliferative neoplasms post-allogeneic stem cell transplantation: more mutations and more methodologies.

Authors:  Stephen E Langabeer; Karl Haslam; Eibhlin Conneally
Journal:  Front Oncol       Date:  2014-08-08       Impact factor: 6.244

Review 7.  Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches.

Authors:  Karl Haslam; Stephen E Langabeer
Journal:  Biomed Res Int       Date:  2016-10-20       Impact factor: 3.411

8.  Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study.

Authors:  J V Jovanovic; A Ivey; A M Vannucchi; E Lippert; E Oppliger Leibundgut; B Cassinat; N Pallisgaard; N Maroc; S Hermouet; G Nickless; P Guglielmelli; B A van der Reijden; J H Jansen; T Alpermann; S Schnittger; A Bench; K Tobal; B Wilkins; K Cuthill; D McLornan; K Yeoman; S Akiki; J Bryon; S Jeffries; A Jones; M J Percy; S Schwemmers; A Gruender; T W Kelley; S Reading; A Pancrazzi; M F McMullin; H L Pahl; N C P Cross; C N Harrison; J T Prchal; C Chomienne; J J Kiladjian; T Barbui; D Grimwade
Journal:  Leukemia       Date:  2013-07-17       Impact factor: 11.528
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.